CagriSema in 2026: What Phase 3 Amylin + GLP-1 Research Shows — and What the Tirzepatide Comparison Changes

Evidence status: Late-stage investigational research. CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. As of September 15, 2026, the combination remains investigational in the United States. Novo Nordisk announced that it submitted a New Drug Application to the FDA on December 18, 2025; an application is not an approval.

Research context only. This article summarizes published and registered clinical research. Trial doses below describe study protocols and are not recommendations for use, dosing, titration, reconstitution, or self-administration.

Why amylin + GLP-1 is scientifically interesting

Much of the recent peptide-metabolism story has centered on incretin biology. CagriSema tests a broader idea: whether combining GLP-1 signaling with an amylin pathway can produce complementary effects on energy intake, satiety and metabolic control. The concept is scientifically important even beyond this particular product because it asks whether multi-pathway peptide pharmacology can improve outcomes without requiring every activity to be built into one receptor agonist.

Cagrilintide is an investigational long-acting amylin analogue, while semaglutide is an established GLP-1 receptor agonist. Their coadministration has now been evaluated in large randomized phase 3 trials.

REDEFINE 1: the strongest published obesity evidence

REDEFINE 1 was a phase 3a randomized trial involving 3,417 adults with obesity, or overweight plus a weight-related complication, without type 2 diabetes. The study compared coadministered cagrilintide and semaglutide with the individual components and placebo over 68 weeks. The study protocol used once-weekly cagrilintide 2.4 mg plus semaglutide 2.4 mg; that dose is reported here only to describe the trial.

In the treatment-policy analysis, estimated mean body-weight change at week 68 was -20.4% with the combination versus -3.0% with placebo. The combination also produced greater mean weight reduction than either component alone. The trial therefore provides strong evidence that amylin-plus-GLP-1 coadministration can produce substantial biological and clinical effects on body weight.

The result also illustrates why estimands matter. Sponsor materials often highlighted approximately 22.7% mean weight reduction under an analysis estimating the effect if participants adhered to treatment. That is a legitimate prespecified way to analyze the trial, but it answers a different question from the treatment-policy estimate of 20.4%. When comparing peptide trials, those numbers should not be treated as interchangeable.

REDEFINE 2: what changed in type 2 diabetes

REDEFINE 2 enrolled 1,206 adults with overweight or obesity and type 2 diabetes. At 68 weeks, estimated mean body-weight change was -13.7% with cagrilintide-semaglutide versus -3.4% with placebo. HbA1c outcomes also favored the combination: 73.5% of participants receiving the combination reached an HbA1c of 6.5% or less compared with 15.9% receiving placebo.

The smaller weight change than in REDEFINE 1 is not surprising in context: obesity pharmacotherapy trials commonly show different weight responses in populations with type 2 diabetes. More importantly, REDEFINE 2 provides independent phase 3 evidence that the combined pathway remains biologically active in a metabolically different population.

Safety: promising efficacy does not eliminate tolerability questions

Gastrointestinal adverse events were common. In REDEFINE 1, gastrointestinal events were reported in 79.6% of participants receiving cagrilintide-semaglutide versus 39.9% receiving placebo. In REDEFINE 2, the corresponding figures were 72.5% and 34.4%. Reported events included nausea, vomiting, diarrhea, constipation and abdominal pain and were mainly transient and mild to moderate.

Those data are important because the value of a multi-pathway strategy is not determined by efficacy alone. Long-term tolerability, treatment persistence, dose flexibility and outcomes beyond body weight will help determine how useful the biology ultimately proves.

The important 2026 update: REDEFINE 4 versus tirzepatide

Sponsor-reported topline data — not yet treated here as peer-reviewed evidence: On February 23, 2026, Novo Nordisk reported headline results from REDEFINE 4, an 84-week, open-label phase 3 head-to-head study involving 809 randomized participants with obesity and at least one comorbidity. The trial compared CagriSema with tirzepatide.

Novo Nordisk reported approximately 23% mean weight loss with CagriSema, but the trial did not meet its primary endpoint of demonstrating non-inferiority to tirzepatide. This is an important negative finding and should not be minimized. It means the strong placebo-controlled efficacy seen in REDEFINE 1 does not automatically establish that CagriSema matches the performance of another highly effective contemporary therapy in a direct comparison.

At the same time, failure of a non-inferiority endpoint does not erase the earlier randomized evidence. It changes the comparative-efficacy question. Full peer-reviewed REDEFINE 4 data will be more informative than topline percentages alone because discontinuations, estimands, achieved doses, adverse events and confidence intervals can materially affect interpretation.

What researchers should watch next

One of the most consequential unanswered questions is whether the amylin component adds benefits beyond weight reduction. REDEFINE 3 is a randomized phase 3 cardiovascular outcomes trial registered on ClinicalTrials.gov with approximately 7,101 participants with established cardiovascular disease. Its primary completion is currently estimated for 2027. Hard cardiovascular outcomes will provide a much stronger test of clinical benefit than changes in predicted risk markers alone.

The broader research program is also exploring different maintenance strategies and further development of amylin-based approaches. Scientifically, this may be the more durable lesson from CagriSema: amylin has re-emerged as a serious partner pathway for metabolic peptide research rather than merely an adjunct to incretin pharmacology.

Limitations and unresolved questions

The pivotal REDEFINE trials were funded by Novo Nordisk, the developer of CagriSema.
REDEFINE 4 results discussed above are sponsor-reported topline findings; full peer-reviewed publication is needed for detailed interpretation.
Weight loss is not equivalent to demonstrated cardiovascular benefit. REDEFINE 3 is designed to address cardiovascular outcomes directly.
Longer-term persistence, adverse-event burden, body-composition effects and outcomes after treatment discontinuation remain important research questions.
Cagrilintide itself remains investigational, and the CagriSema combination should not be treated as equivalent to separately sourced or compounded materials.

Regulatory context

Novo Nordisk announced an FDA New Drug Application for CagriSema in December 2025. As of this article’s September 15, 2026 evidence review, we found no FDA approval announcement for CagriSema. The FDA has separately taken enforcement action against online sellers marketing cagrilintide as an unapproved drug, underscoring the distinction between a compound being studied in clinical trials and an FDA-approved finished medicine.

Bottom line

CagriSema provides some of the strongest human evidence yet that pairing amylin and GLP-1 biology can produce substantial metabolic effects. REDEFINE 1 and REDEFINE 2 are large, peer-reviewed phase 3 trials and support the scientific promise of the combination. The 2026 REDEFINE 4 topline result adds an equally important constraint: in a direct comparison, CagriSema did not demonstrate non-inferiority to tirzepatide on its primary weight-loss endpoint.

That combination of positive and negative evidence is scientifically useful. The next major questions are less about whether the pathway can reduce weight—it clearly can in controlled trials—and more about comparative effectiveness, tolerability, cardiovascular outcomes and whether amylin-based combinations can provide advantages that matter beyond the scale.

Sources

Editorial disclosure: LoCo Research Journal is affiliated with LoCo Research Supply. This article is an evidence review and is editorially separate from commercial product descriptions. No commercial affiliation changes the evidence grading or regulatory status described above.